Evidence map›Paper›PMID 35500795›Full record

ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2022

A Fatal Breakthrough COVID-19 Case Following Bendamustine-Rituximab Therapy.

Kohei Kamegai, Noriko Iwamoto, Tomiteru Togano, Kenji Maeda, Yuki Takamatsu, Yusuke Miyazato, Masahiro Ishikane, Masashi Mizokami, Masaya Sugiyama, Shun Iida and 3 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Kohei KamegaiNational Center for Global Health and Medicine, Tokyo, Japan.
Noriko IwamotoNational Center for Global Health and Medicine, Tokyo, Japan. Electronic address: nkinoshita@hosp.ncgm.go.jp.
Tomiteru ToganoNational Center for Global Health and Medicine, Tokyo, Japan.
Kenji MaedaDepartment of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute.
Yuki TakamatsuDepartment of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute.
Yusuke MiyazatoNational Center for Global Health and Medicine, Tokyo, Japan.
Masahiro IshikaneNational Center for Global Health and Medicine, Tokyo, Japan.
Masashi MizokamiNational Center for Global Health and Medicine, Tokyo, Japan.
Masaya SugiyamaNational Center for Global Health and Medicine, Tokyo, Japan.
Shun IidaDepartment of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.
Sho MiyamotoDepartment of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.
Tadaki SuzukiDepartment of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.
Norio OhmagariNational Center for Global Health and Medicine, Tokyo, Japan.
National Center for Global Health and Medicine · JPNational Institute of Infectious Diseases · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although messenger ribonucleic acid vaccines are substantially effective toward SARS-CoV-2 infection, patients with hematologic malignancies are still prone to the virus. Herein, we report a fatal case of breakthrough SARS-CoV-2 Delta variant infection in a patient with mucosa-associated lymphoid tissue lymphoma with remission by bendamustine-rituximab (BR) therapy completed a year ago. The serologic study revealed impaired responsiveness toward vaccines and prolonged high viral load after infection. BR therapy seemingly induced an immune escape. Prevention and treatment strategies for such vulnerable patients should be clarified immediately.

Indexed as

COVID-19 Drug TreatmentSARS-CoV-2Antineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideHumansRituximabBendamustine HydrochlorideRituximabBendamustine-rituximab therapyBreakthroughCOVID-19FatalImmune escape

Identifiers

PMID35500795
PMCPMC9054701
OpenAlexW4225150423

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.